 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > diaDexus, Inc.
 |
diaDexus, Inc. |
 |
 |
 |
PROFILE |
 |
diaDexus works to detect deadly diseases. The company uses raw genomics data to develop diagnostic tests for such conditions as coronary heart disease, osteoporosis, and colorectal, breast, and other cancers. Lead products in development include Lp-PLA(2) for coronary heart disease and Cathepsin-K for osteoporosis. diaDexus also plans to develop therapeutics with a focus on monoclonal antibodies, which target disease-associated proteins found on the surface of cells. diaDexus was founded by genomics leaders SmithKline Beecham (now GlaxoSmithKline) and Incyte Genomics, which provide it with genomic data and potential molecular targets; each owns roughly 20% of the company.
COMPETITION |
 |
Abbott Laboratories (ABT)
Millennium Pharmaceuticals, Inc. (MLNM)
Myriad Genetics, Inc. (MYGN)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
1999 Sales (mil.): 0.10
Employees: 36
Revenue per employee: $2,777.78
KEY PEOPLE |
 |
Patrick Plewman
CEO
Sharon E. Tetlow
CFO
CONTACT INFO |
 |
3303 Octavius Dr.
Santa Clara, CA 95054
US
Phone: 408-496-6600
Fax: 408-496-5777
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |